Abstract
Lipopolysaccharide (LPS), a bacterial endotoxin, triggers deleterious systemic inflammatory responses when released into blood circulation, causing organ dysfunction and death. In response to LPS stimulation, CD14 and toll-like receptor (TLR)-4 elicit inflammatory signaling cascades. Although leukocyte integrins (CD11b/CD18 and CD11c/CD18) were reported to bind LPS and induce NF-κB translocation, the evidence on such epitope location remains elusive. The present study aims to delineate the LPS-binding sites on the integrin CD18 antigen and to design peptide(s) as potential prophylactic and/or therapeutic agents to modulate LPS effects in activated Jurkat cells. Epitope mapping analysis using a series of CD18 truncated variants revealed two putative LPS-binding sites within the βA region (216-248 and 266-318 a.a.), which were further confirmed by point mutation studies. Inhibition assay demonstrated that the CD18-βA266-318 peptide could block LPS binding in a dosedependent manner. Our data also indicated that treatment with the CD18-peptide modulated TNF-α mRNA transcription via the NF-κB signaling pathway in LPS-activated Jurkat cells. In conclusion, we have identified two novel LPS-binding sites located at the CD18 βA domain of leukocyte integrin, and the integrin peptide βA266-318 is shown to inhibit LPS binding and subsequent inflammatory events, having therapeutic implications to cure Gram-negative endotoxemia.
Original language | English (US) |
---|---|
Pages (from-to) | 3231-3239 |
Number of pages | 9 |
Journal | FASEB Journal |
Volume | 21 |
Issue number | 12 |
DOIs | |
State | Published - Oct 2007 |
Keywords
- Endotoxin-neutralizing peptide
- Lipopolysaccharide
- NF-κB
- Prophylaxis
- Sepsis
- TNF-α
ASJC Scopus subject areas
- Agricultural and Biological Sciences (miscellaneous)
- Biochemistry, Genetics and Molecular Biology(all)
- Biochemistry
- Cell Biology
- Medicine(all)